Ali Ediz Kivanc

Ali Ediz Kivanc

Auto-generated profile, based on publicly available information

Ali Ediz Kivanc

Yeditepe University, Faculty of Medicine

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2026 in Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
AKAli Ediz Kıvanç
Ali Ediz Kıvanç
MOMehmet Oduncu
Mehmet Oduncu
PÖPirilti Özcan
Pirilti Özcan
ÖDÖzgül Düzgün
Özgül Düzgün
NKNeşet Köksal
Neşet Köksal
Background and Objectives: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is established for peritoneal surface malignancies, but its use in older patients is debated. We assessed CRS‐HIPEC morbidity and mortality in patients aged ≥ 70 years using a cohort of younger patients as a comparator. Methods: We retrospectively reviewed consecutive patients aged ≥ 70 and < 70 undergoing CRS‐HIPEC for peritoneal carcinomatosis at two centers (2017−2026). Peritoneal carcinomatosis index (PCI), completeness of cytoreduction (CC), complications (Clavien‐Dindo), and mortality were analyzed. Results: Ninety‐five patients were included (53 female; mean age 74.7 years; 10 [10.5%] aged ≥ 80; 70 [73.7%] ASA III−IV). Commonest primaries: colorectal (40), gastric (14), ovarian (12). Mean PCI was 15.6; complete cytoreduction (CC‐0) was achieved in 58.9%. Complications were Clavien‐Dindo grade III−IV in 11.6%, and grade V in 3.2%; major morbidity (≥ III) was 14.7%. Longer operative time ( p = 0.013) and intraoperative transfusion ( p = 0.027) were associated with major morbidity in the elderly cohort, whereas age was not ( p = 0.161). Overall mortality was 12/95 (12.6%). Conclusions: In selected patients aged ≥ 70 years, CRS‐HIPEC achieved morbidity and mortality comparable to the younger group, with most complications low‐grade. Advanced age alone should not preclude CRS‐HIPEC; candidacy depends on comorbidity, performance status, and the likelihood of complete cytoreduction.

9 October 2026 in International Journal of Surgical Pathology
Verified
Journal Article
Closed access
EHEzgi Hacıhasanoğlu
Ezgi Hacıhasanoğlu
AAAysegul Isal Arslan
Aysegul Isal Arslan
AKAli Ediz Kivanc
Ali Ediz Kivanc
Background: Extranodal extension, defined as tumor invasion beyond the lymph node capsule into perinodal adipose tissue, has been associated with adverse outcomes in several malignancies but is not included in the AJCC-TNM staging system for colorectal cancer. This study evaluated the clinicopathological and prognostic significance of extranodal extension and its extent in lymph node-positive colorectal carcinoma. Methods: Sixty-nine patients who underwent curative-intent resection for lymph node-positive colorectal carcinoma were retrospectively analyzed. Patients were classified according to the presence of extranodal extension, and extranodal extension-positive tumors were further categorized as limited (<1 mm) or extensive (≥1 mm). Associations with clinicopathological variables and survival outcomes were analyzed using Cox proportional hazards regression models. Results: Extranodal extension was identified in 29 patients (42%) and was associated with a higher metastatic lymph node count, higher N stage, and an increased incidence of distant metastasis (all P < .05). In multivariate analysis adjusted for T stage, N stage, and postoperative adjuvant chemotherapy, extranodal extension remained independently associated with shorter disease-free survival (hazard ratio 2.65; 95% confidence interval 1.10-6.38; P = .031). Extranodal extension was not independently associated with overall survival. Although the extent of extranodal extension correlated with nodal burden, it was not independently associated with survival outcomes. Conclusion: Extranodal extension is associated with increased nodal tumor burden and independently predicts shorter disease-free survival in colorectal carcinoma. Routine assessment and reporting of extranodal extension may improve pathological risk stratification.